Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) の総合的な財務健全性評価は B+ 総合スコア 0 （5点満点）.
これは注視すべき財務上の課題があることを示唆しています. 評価日 2026-03-18.
| 日付 | 評価 | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-01-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
